Kuang He is Vice President in Seed Investments at Novo Holdings. Kuang serves as a Board Observer for Antag Therapeutics, Booster Therapeutics, Tribune Therapeutics, and RheumaLogics. Before joining Novo Holdings, Kuang worked at Sofinnova Partners in Paris, focusing on late-stage investments in pharmaceuticals and medtech. Kuang holds a B.S. from Peking University and a Ph.D. in Biochemistry from Indiana University, Bloomington. She was recognized with a Clinical and Translational Science Award by the National Institutes of Health (NIH) during her postdoctoral training in the Division of Hematology/Oncology at the University of Michigan. 

.